IdentifAI

IdentifAI Genetics is a biotechnology company that provides non-invasive prenatal screening tests for genetic syndromes, utilizing proprietary data science algorithms and bioinformatics technology to provide an overview of fetal health at an early stage of pregnancy. The company platform analyzes cell-free DNA from maternal blood samples to detect chromosomal abnormalities and genetic conditions, offering expectant parents and healthcare providers actionable information for pregnancy management. The technology combines advanced sequencing techniques with machine learning algorithms to improve detection accuracy while reducing false positive rates compared to traditional screening methods. Founded in 2020 and headquartered in Tel Aviv, Israel, IdentifAI has raised approximately $9.8 million in Series A funding from investors including eHealth Ventures, Shizim, and Innovation Israel.